"Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.

MLA

Fang, Youqiang, et al. “‘Combi-Targeting’ Mitozolomide: Conferring Novel Signaling Inhibitory Properties to an Abandoned DNA Alkylating Agent in the Treatment of Advanced Prostate Cancer.” The Prostate, vol. 72, no. 12, Sept. 2012, pp. 1273–85. EBSCOhost, https://doi.org/10.1002/pros.22475.

APA

Fang, Y., Qiu, Q., Domarkas, J., Larroque-Lombard, A.-L., Rao, S., Rachid, Z., Gibbs, B. F., Gao, X., & Jean-Claude, B. J. (2012). “Combi-targeting” mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. The Prostate, 72(12), 1273–1285. https://doi.org/10.1002/pros.22475

Chicago

Fang, Youqiang, Qiyu Qiu, Juozas Domarkas, Anne-Laure Larroque-Lombard, Suman Rao, Zakaria Rachid, Bernard F Gibbs, Xin Gao, and Bertrand J Jean-Claude. 2012. “‘Combi-Targeting’ Mitozolomide: Conferring Novel Signaling Inhibitory Properties to an Abandoned DNA Alkylating Agent in the Treatment of Advanced Prostate Cancer.” The Prostate 72 (12): 1273–85. doi:10.1002/pros.22475.